

Pharmacotherapy for Opioid Use Disorder (POD)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS[®]) helps us measure many aspects of performance. This tip sheet provides key details of the HEDIS measure for opioid use disorder.

What is the measure?

The measure monitors members age 16 and older with a diagnosis of opioid use disorder (OUD) and a new OUD pharmacotherapy event that lasted at least 180 days.

Note:

- Members can have multiple treatment period start dates and treatment periods during the measurement year.
- Pharmacy and medical claims qualify member for the measure and determine compliance.
- Medication administration and dispensing events occurring during the treatment period.
- Methadone **is not** included because it is indicative of treatment for pain rather than OUD.

Exclusions

- Any acute or nonacute inpatient stay of eight or more days during the treatment period
- Members in hospice or using hospice services during the measurement year
- Members who died during the measurement year

Exclusion Codes

Hospice Encounter

HPCPS

G9473 – G9479, Q5003 – Q5008, Q5010, S9126, T2042 – T2046

Hospice Intervention

CPT

99377 – 99378

HPCPS

G0182

Codes for Reporting Opioid Use

Description

Opioid Use and Dependence

ICD10

F11.10, F11.120 – F11.122, F11.129, F11.13 – F11.14, F11.150 – F11.151, F11.159, F11.181 – F11.182, F11.188, F11.19 – F11.20, F11.220 – F11.222, F11.229, F11.23 – F11.24, F11.250 – F11.251, F11.259, F11.281 – F11.282, F11.288, F11.29

Continued next page

All summaries of the measures contained herein are reproduced with permission from HEDIS *Volume 2: Technical Specifications for Health Plans* by the National Committee for Quality Assurance (NCQA). HEDIS[®] is a registered trademark of the NCQA. Please see the final page of this document for the full copyright citation.

Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.

113560 0323

HEDIS Measurement: Pharmacotherapy for Opioid Use Disorder (POD) (continued)

Opioid Use Disorder Treatment Medications

Description	Prescription
Antagonist	Naltrexone (oral)
Antagonist	Naltrexone (injectable)
Partial agonist	Buprenorphine (sublingual tablet)
Partial agonist	Buprenorphine (injection)
Partial agonist	Buprenorphine (implant)
Partial agonist	Buprenorphine/ naloxone (sublingual tablet, buccal film, sublingual film)
Agonist	Methadone (oral)

Content reproduced with permission from *HEDIS® MY 2023, Volume 2: Technical Specifications for Health Plans* by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit ncqa.org/publications.